1. Home
  2. IBRX vs HIMS Comparison

IBRX vs HIMS Comparison

Compare IBRX & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$8.72

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Logo Hims & Hers Health Inc.

HIMS

Hims & Hers Health Inc.

HOLD

Current Price

$28.78

Market Cap

6.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
HIMS
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
6.9B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
IBRX
HIMS
Price
$8.72
$28.78
Analyst Decision
Strong Buy
Hold
Analyst Count
7
15
Target Price
$12.57
★ $30.46
AVG Volume (30 Days)
★ 9.0M
8.1M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.71
N/A
EPS
N/A
★ N/A
Revenue
$113,288,000.00
★ $2,347,637,000.00
Revenue This Year
$88.59
$19.82
Revenue Next Year
$131.15
$19.23
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 668.31
59.00
52 Week Low
$1.95
$13.74
52 Week High
$12.43
$65.30

Technical Indicators

Market Signals
Indicator
IBRX
HIMS
Relative Strength Index (RSI) 56.93 48.18
Support Level $6.68 $27.36
Resistance Level $9.54 $30.10
Average True Range (ATR) 0.54 1.50
MACD 0.02 0.16
Stochastic Oscillator 57.88 37.99

Price Performance

Historical Comparison
IBRX
HIMS

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About HIMS Hims & Hers Health Inc.

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Share on Social Networks: